Dissolution Development Of Parvulet® Technology Oral Tablets
By Jennifer A. Neuforth, Analytical Scientist, R&D; Jeffrey Hargrave, Sr. Manager, R&D Analytical Sciences; Michael Markham, Associate Director, R&D Analytical Sciences, Adare Pharma Solutions
Parvulet® Technology is a patented oral dosage form capable of being dispensed to patients in tablet or powder formats, and converted into a semi-solid at the time of dosage through activation with water. The final dosage is easily administered, as a soft food like texture, ideal for pediatric and geriatric populations (including those with dysphagia). The Parvulet® technology can be combined with our taste-masking and controlled release technologies, providing greater flexibility in advancing patient centric solutions. (see Figure 1 below).
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.